| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
178.65(B) |
| Last
Volume: |
1,924,998 |
Avg
Vol: |
2,723,980 |
| 52
Week Range: |
$217.36 - $324.56 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 499 |
| Guru Rank Value : 3 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,117 |
2,117 |
23,771 |
31,503 |
| Total Sell Value |
$662,802 |
$662,802 |
$6,471,520 |
$8,438,219 |
| Total People Sold |
1 |
1 |
3 |
6 |
| Total Sell Transactions |
1 |
1 |
4 |
8 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Such Annette Louise |
VP, Finance and CAO |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
575 |
10,414 |
|
- |
|
| Tross Stuart A |
SVP, Human Resources |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,046 |
25,671 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,023 |
32,359 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,023 |
21,901 |
|
- |
|
| Hooper Anthony C |
EVP, Global Commercial Ops. |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
5,116 |
189,312 |
|
- |
|
| Mcnamee Brian M |
EVP |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,581 |
91,989 |
|
- |
|
| Graham Jonathan P |
SVP, Gen. Counsel & Secy. |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,942 |
52,982 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,477 |
46,725 |
|
- |
|
| Balachandran Madhavan |
EVP, Operations |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,581 |
23,097 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
14,070 |
354,945 |
|
- |
|
| Williams R Sanders |
Director |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,279 |
2,779 |
|
- |
|
| Sugar Ronald D |
Director |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,279 |
9,801 |
|
- |
|
| Pelham Judith C |
Director |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,279 |
13,169 |
|
- |
|
| Jacks Tyler |
Director |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,279 |
6,255 |
|
- |
|
| Herringer Frank C |
Director |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,279 |
30,268 |
|
- |
|
| Henderson Rebecca M |
Director |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,279 |
10,171 |
|
- |
|
| Hassan Fred |
Director |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,279 |
4,861 |
|
- |
|
| Eckert Robert |
Director |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,279 |
6,755 |
|
- |
|
| Garland Greg C. |
Director |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,279 |
4,694 |
|
- |
|
| De Carbonnel Francois |
Director |
• • – |
2016-05-03 |
4 |
D |
$158.99 |
$48,810 |
D/D |
(307) |
16,159 |
|
- |
|
| De Carbonnel Francois |
Director |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,279 |
16,466 |
|
- |
|
| Coffman Vance D |
Director |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,279 |
43,041 |
|
- |
|
| Biondi Frank |
Director |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,279 |
34,930 |
|
- |
|
| Baltimore David |
Director |
• • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,279 |
33,629 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• – – |
2016-04-29 |
4 |
S |
$157.99 |
$3,456,134 |
D/D |
(21,875) |
42,248 |
|
- |
|
2206 Records found
|
|
Page 30 of 89 |
|
|
0.67 (0.22%) 
